Previously, the activation of the β3-AR, in a PPAR-γ-dependent manner, was able to ameliorate liver steatosis and inflammation in nonalcoholic fatty liver disease (Wang et al., 2020), to cause the browning of white adipocytes to cure obesity (Fan et al., 2019), to offer anti-atherosclerotic effects (Shi et al., 2014), and to hinder preterm labor onset (Hadi et al., 2017). Here, ADRB3 is linked to metabolic dysfunction-associated steatotic liver disease.